KUALA LUMPUR, 26 February 2026 — Optimax Holdings Berhad reported record revenue for the financial year ended 31 December 2025 (FYE2025), supported by regional expansion and sustained demand for its eye specialist services.
For the fourth quarter ended 31 December 2025 (Q4FYE2025), revenue rose 5.3% year-on-year (Y-o-Y) to RM36.1 million, compared with RM34.3 million in the corresponding quarter a year earlier. The Group attributed the growth to effective online marketing initiatives and contributions from its regional expansion.
Profit before tax (PBT) for the quarter increased 0.9% Y-o-Y to RM5.1 million, while profit after tax (PAT) rose 3.1% to RM3.5 million.
For the full year, Optimax recorded revenue of RM135.7 million, representing a 6.3% Y-o-Y increase from RM127.7 million in FYE2024. PBT grew 1.5% to RM20.3 million, while PAT climbed 3.8% to RM14.9 million.
Excluding a one-off RM0.7 million write-off of assets, normalised PBT would have been RM21.0 million, translating into a 5.0% growth over the previous year.
The Board of Directors proposed a second interim dividend of 0.6 sen per ordinary share for FYE2025, with an entitlement date of 16 March 2026 and payment scheduled for 30 March 2026. Total dividends declared for FY2025 amount to 1.40 sen per share, up from 1.30 sen in the preceding year, resulting in a payout ratio of 55.3%.
Chief executive officer Sandy Tan said the Group’s regional strategy had emerged as a key growth driver.
“We are pleased to close 2025 with steady revenue growth. Our investment strategies in regional expansion have proven successful, with our Cambodia and East Malaysia operations emerging as significant growth engines, achieving full-year revenue growth of 135.5% and 77.5%, respectively. The inclusion of our newly operational centre in Sabah has specifically enhanced the revenue contribution from our East Malaysian operations. By optimising the utilisation rates of our newly established centres, we have managed to sustain growth despite higher operating and maintenance costs.
“As we move into 2026, we look forward to further diversifying our geographical footprint. The Group remains committed to explore advanced technologies and expand its clinical capabilities both domestically and in overseas markets to better serve the evolving needs of the patients. This will reinforce our leadership in the eye healthcare industry,” she added.
